Normal or improved cardiovascular risk factors in IGF-I-deficient adults with growth hormone receptor deficiency
Read the full article here
Related Articles
The Impact of Screening Practices for Black Men – Leanne Woods-Burnham
Samuel Washington engages with Leanne Woods-Burnham to delve into prostate cancer screening for Black men in the U.S., highlighting their discussion at the SUO conference.…
iOS 18: Audio Transcriptions Rumored for Notes and Voice Memos Apps
iOS 18 will include new audio transcription features in the Voice Memos and Notes apps, according to information obtained by AppleInsider. The…
Prevalence of omalizumab resistant chronic urticaria and real world effectiveness of dupilumab in omalizumab refractory chronic urticaria patients: a single center experience
“A blog about allergy, asthma & immunology”
4-Star Review of Spinal Cord Injury, 1st Edition – The Bookmark
This book is an overview of the basic topics of spinal cord injury medicine for those pursuing spinal cord injury medicine boards.
What doctors wish patients knew about the deadly risk of stroke
During a stroke, every second counts. That is why it is important to know and recognize symptoms early. Two physicians share more.
Systemic Lupus Erythematosus
This review summarizes current evidence regarding the diagnosis, treatment, and prognosis of systemic lupus erythematosus.
An Update on Patient-Reported Outcomes in Asthma
Patient-reported outcomes (PROs) are information provided by patients on their condition, function, well-being, or experience. Instruments to quantify…
6th Annual New England Pediatric Hospital Medicine Conference
06/03/2024 event : Welcome to the 6th annual New England Pediatric Hospital Medicine Conference (NEPHM), June 3, 2024. NEPHM 2024 will be presented via a…
Contact NCI
Information specialists at NCI’s Cancer Information Service (CIS), NCI’s contact center, are available to help answer your cancer-related questions whether you are a patient, family…
Six-Year Imatinib Maintenance Therapy Reduces Recurrence Risk in GIST
Investigators found that imatinib maintenance therapy for 6 years reduced the risk of recurrence in patients with gastrointestinal stromal tumors.
